A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunityJodi L. Karnell, Jörn Drappa, Vaheh Oganesyan et al.|Science Translational Medicine|2019Cited by 98
Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorderOrhan Aktaş, Bruce Cree, Hans‐Peter Hartung et al.|Journal of Neurology Neurosurgery & Psychiatry|2023Cited by 47
Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trialJeffrey L. Bennett, Bruce Cree, Orhan Aktaş et al.|EBioMedicine|2022Cited by 42